therapy (cART) regimens can minimize disease progression by reducing viral loads for HIV-infected individuals, they do not address challenges posed by persistent viral reservoirs, therapeutically elusive physiological compartments and the development of drug resistance. New therapeutic agents useful to reduce persistent and elusive virus represent the next evolution for HIV treatment. Jericho Sciences collaborates with academic, government and industrial researchers and maintains a strong intellectual property position for all portfolio projects.